Drug intelligence / Profile preview

Infanrix + Prevenar 13

Development stage
Unknown
Lead developer
Pfizer
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Infanrix + Prevenar 13 refers to the simultaneous administration of two pediatric vaccines: Infanrix, a hexavalent combination vaccine (DTPa-HBV-IPV/Hib) that protects against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and *Haemophilus influenzae* type b; and Prevenar 13 (Pneumococcal 13-valent Conjugate Vaccine), which protects against infections caused by thirteen serotypes of *Streptococcus pneumoniae*. Both are inactivated vaccines administered intramuscularly at different injection sites during the same visit. The mechanism of action for both is immunization via induction of specific antibodies against their respective antigens. This co-administration is common in national immunization programs to provide broad protection in infancy[3][4][7].

Other names
DTPa-HBV-IPV/Hib + Pneumococcal 13-valent Conjugate VaccineHexavalent vaccine + PCV13
02

Targets

PV3 (Sabin) (Poliovirus type 3 antigen)HBsAg (Hepatitis B surface antigen)Diphtheria toxinStreptococcus pneumoniae capsular polysaccharide–CRM197 conjugate

Beyond the preview

Go deeper on Infanrix + Prevenar 13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infanrix + Prevenar 13.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call